UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 8:45 a.m. ET. The webcast of the presentation will b
EQSAdhoc PUMA SE Key word Share BuybackDividend PUMA SE PUMA plans to return up to 50% of net income to shareholders including share buybacks 29Feb2024 0934 CETCEST Disclosure of an inside informatio
EQS-Ad-hoc: PUMA SE / Key word: Share Buyback/Dividend
PUMA SE: PUMA plans to return up to 50% of net income to shareholders, including share buybacks
29-Feb-2024 / 09:34.
EQS-Ad-hoc: PUMA SE / Key word: Annual Results/Preliminary Results
PUMA SE: PUMA announces preliminary results for the financial year 2023 and outlook for 2024
24-Jan-2024 / 09:35.